Coxiella burnetii epitopes for T cell-targeted Q fever vaccines
AssigneesThe General Hospital Corporation, EpiVax, Inc., Innatoss Laboratories B.V.
InventorsMark C. Poznansky, Ann Elizabeth Sluder, Timothy Alan Brauns, Anne Searls De Groot, Leonard Jeffrey Moise, Anja Garritsen, Anja Scholzen
Life of this patent
Estimating the term…
Abstract
Compositions and methods for inducing a protective immune response against Coxiella burnetii, to reduce a subject's risk of developing Q fever.
Claims13
A composition comprising one or more isolated nucleic acids encoding a polypeptide comprising three or more epitope peptides of Coxiella burnetti source antigens, wherein the three or more epitope peptides are selected from the group consisting of p4, p12, p14, p15, p17, p18, p20, p21, p22, p26, p27, p30, p37, p38, p42, p43, p45, and p48, each of which consists of SEQ ID NO:
- 4, SEQ ID NO:
- 12, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:18, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 30, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 45, and SEQ ID NO:
- 48 respectively, optionally with linkers therebetween, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.